HepaLife in license deal with US

HepaLife Technologies Inc., a Boston company engaged in the development of cell-based medical technologies, said today that it has entered into an exclusive license agreement with the US Department of Agriculture.

The agreement allows for the use of patented liver cell lines in artificial liver devices and in-vitro toxicological testing platforms, HepaLife said.

Financial details of the agreement were not disclosed.
(By Chris Reidy, Globe staff)